Evaluating the effects of sevelamer carbonate on cardiovascular structure and function in chronic renal impairment in Birmingham: the CRIB-PHOS randomised controlled trial by Chue, Colin D et al.
STUDY PROTOCOL Open Access
Evaluating the effects of sevelamer carbonate on
cardiovascular structure and function in chronic
renal impairment in Birmingham: the CRIB-PHOS
randomised controlled trial
Colin D Chue
1, Jonathan N Townend
1, Richard P Steeds
1, Charles J Ferro
2*
Abstract
Background: Serum phosphate is an independent predictor of cardiovascular morbidity and mortality in patients
with chronic kidney disease and the general population. There is accumulating evidence that phosphate promotes
arterial stiffening through structural vascular alterations such as medial calcification, which are already apparent in
the early stages of chronic kidney disease.
Aim: To determine the effects of phosphate binding with sevelamer carbonate on left ventricular mass and
function together with arterial stiffness in patients with stage 3 chronic kidney disease.
Methods/Design: A single-centre, prospective, randomised, double-blind, placebo-controlled trial of 120 subjects
with stage 3 chronic kidney disease recruited from University Hospitals Birmingham NHS Foundation Trust. Baseline
investigations include transthoracic echocardiography and cardiac magnetic resonance imaging to assess
ventricular mass, volumes and function, applanation tonometry to determine pulse wave velocity and pulse wave
analysis as surrogate measures of arterial stiffness and dual energy x-ray absorptiometry scanning to determine
bone density. During an open-label run in phase, subjects will receive 1600 mg sevelamer carbonate with meals
for four weeks. They will then be randomised to either continue sevelamer carbonate or receive an identical
placebo (60 subjects per arm) for the remaining 36 weeks. Four-weekly monitoring of serum electrolytes and bone
biochemistry will be performed. All baseline investigations will be repeated at the end of the treatment period. The
primary endpoint of the study is a reduction in left ventricular mass after 40 weeks of treatment. Secondary
endpoints are: i) change in aortic compliance; ii) change in arterial stiffness; iii) change in arterial elastance;
iv) change in left ventricular systolic and diastolic elastance; v) change in left ventricular function; and vi) change in
bone density.
Trial Registration: This trial is registered at ClinicalTrials.gov: NCT00806481 and Current Controlled Trials:
ISRCTN35254279.
Background
The risk of cardiovascular disease is elevated in patients
w i t hc h r o n i ck i d n e yd i s e a s e( C K D )w i t ha ni n v e r s e
graded relationship to glomerular filtration rate (GFR)
independent of other risk factors [1]. The magnitude of
this excess risk varies according to age, but for patients
with moderately impaired renal function at stage 3b
CKD (GFR 30-44 ml/min/1.73 m
2), cardiovascular risk
is at least doubled [2]. Although cardiovascular risk in
end stage kidney disease (ESKD) is elevated, the global
burden of cardiovascular disease caused by early CKD is
much greater in public health terms as approximately
10% of the general population have a GFR within the
CKD stage 3 range (30-59 ml/min/1.73 m
2)[ 3 ] .T h e s e
individuals are much more likely to die from cardiovas-
cular disease than progress to ESKD [4].
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only account for a minority of cardiovascular deaths in
patients with CKD, the remainder being attributable to
congestive heart failure, sudden cardiac death and
arrhythmia [5]. These appear to be driven by underlying
structural abnormalities such as left ventricular hypertro-
phy, fibrosis and dysfunction, which are near universal in
patients with CKD and are present even in the early
stages of disease [6]. Recent work suggests that increased
arterial stiffness plays a major role in the development of
these myocardial abnormalities, and both increased left
ventricular mass and increaseda r t e r i a ls t i f f n e s sa r eo f
proven prognostic significance in CKD [7-10].
Serum phosphate is an independent predictor of cardi-
ovascular morbidity and mortality in patients with CKD
[11] and within the general population [12]. Reasons for
this are unclear, but phosphate is intimately involved in
the regulation of medial vascular smooth muscle growth
and calcification giving rise to the possibility that it is
acting as a mediator of increased arterial stiffness. Phos-
phate binders administered to control hyperphosphatae-
mia in CKD might therefore be expected to reduce or
slow the progression of arterial stiffness in addition to
their primary role of preventing metabolic bone disease.
The non-calcium-based phosphate binder sevelamer,
which reduces hyperphosphataemia without increasing
calcium-phosphate product, has near ideal pharmacolo-
gical properties for such an action. Indeed, in three ran-
d o m i s e dc o n t r o l l e dt r i a l si th a sb e e ns h o w nt ob e
superior to calcium-based phosphate binders in attenu-
ating the progression of coronary artery and aortic calci-
fication [13-15].
Although serum phosphate rises early in the course of
CKD, phosphate binders are currently only used in late-
stage disease when major abnormalities of calcium and
phosphate metabolism are present. By this time it is
likely that arterial and ventricular function are already
significantly impaired, partly through prolonged expo-
sure of the vascular system to high levels of phosphate.
This study aims to examine the effect of phosphate
binding with sevelamer on left ventricular mass, markers
of arterial stiffness and left ventricular function in early
stage CKD.
Methods
Hypothesis
Phosphate binding with sevelamer carbonate will reduce
left ventricular mass, improve indices of left ventricular
systolic and diastolic function, and reduce arterial and
cardiac stiffness in patients with stage 3 CKD.
Study Design
This is a single-centre prospective, randomised, double-
blind, placebo-controlled trial of 120 subjects with stage 3
CKD (defined as an estimated GFR 30-59 ml/min/1.73 m
2)
established on conventional treatment with an angiotensin
converting enzyme inhibitor or angiotensin receptor
blocker for at least 3 months before enrolment. GFR will
be estimated by the 4-variable Modification of Diet in
Renal Disease formula with serum creatinine recalibrated
to be traceable to an isotope derived mass spectroscopy
method [16]. Inclusion and exclusion criteria are detailed
in Table 1.
Baseline Studies
All subjects will undergo a baseline visit (Figure 1) during
which the following will be performed: i) questionnaire
regarding past medical history, drug history and tobacco
and alcohol consumption; ii) clinical examination of all
systems; iii) measurement of height, weight, hips and
waist; iv) 12-lead electrocardiogram (ECG); v) office bra-
chial blood pressure and heart rate measurement in tripli-
cate using the non-dominant arm following 15 minutes of
rest with a validated oscillometric sphygmomanometer
(HEM-705CP, Omron, Henfield, United Kingdom [17] or
Dinamap Procare 200, GE Healthcare, United Kingdom
[18]) according to British Hypertension Society guidelines
[19]; vi) applanation tonometry to determine carotid-
femoral aortic pulse wave velocity; vii) applanation tono-
metry to derive central pressure waveforms from pulse
wave analysis and to determine central systolic and diasto-
lic pressures and augmentation index; viii) dual energy
x-ray absorptiometry (DEXA) scanning to assess bone
mineral density as recommended by the World Health
Organisation [20,21]; ix) collection of serum and plasma
following 30 minutes of supine rest for haematological
and biochemical analysis including serum calcium,
Table 1 Inclusion and exclusion criteria
Inclusion Criteria
Age 18-80 years
Chronic kidney disease stage 3 (estimated GFR 30-59 ml/min/1.73 m
2)
Office BP controlled to <140/90 mmHg for ≥12 months before entry
Total cholesterol <5.5 mmol/L
Exclusion Criteria
Existing or previous treatment within the past year with a phosphate
binder or vitamin D analogue
Hyperphosphataemia (serum phosphate >1.8 mmol/L)
Hypophosphataemia (serum phosphate <0.8 mmol/L)
Uncontrolled secondary hyperparathyroidism (PTH >80 pg/ml)
Diabetes mellitus
Pregnancy
Women of child-bearing age not on contraception
Bowel obstruction
Dysphagia or other swallowing disorder
Severe gastrointestinal motility disorders including severe constipation
Previous major gastrointestinal tract surgery
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mone (PTH); x) storage of serum and plasma at -80°C for
future assay of biomarkers associated with cardiovascular
function and calcification; xi) collection of a spot urine
sample to determine albumin: creatinine ratio; xii) storage
of a spot urine sample at -80°C for future proteomic stu-
dies; xiii) transthoracic echocardiography to determine
systolic and diastolic ventricular function and measures of
ventricular-vascular interaction; xiv) a lateral plain abdom-
inal radiograph to semi-quantitatively assess abdominal
aortic calcification as previously described [22]; xv) cardiac
magnetic resonance imaging (CMR) to determine ventri-
cular volumes, function and mass and aortic distensibility
as previously described [23]; xvi) 24-hour urine collection
for determination of phosphate excretion; and xvii)
24-hour ambulatory blood pressure and heart rate
monitoring with a validated ambulatory blood pressure
monitor (ABPM-04, Meditech, Budapest, Hungary) [24].
Eligible female subjects of childbearing age will undergo
urine pregnancy testing prior to entry into the study.
Cardiac Magnetic Resonance Imaging
Cardiac magnetic resonance imaging will be performed
using a 1.5-T scanner (Sonata Symphony, Siemens,
Erlangen, Germany) with subjects in the supine position.
Serial contiguous short axis cines will be piloted from
the vertical long axis and horizontal long axis images of
the left and right ventricles (ECG R wave-gated, steady-
state free precession imaging [True-FISP]; temporal
resolution 40-50 ms, repetition time 3.2 ms, echo time
1.6 ms, flip angle 60°, slice thickness 7 mm with 3 mm
gap) in accordance with previously validated methodolo-
gies [23]. Analysis will be performed offline (Argus Soft-
w a r e ,S i e m e n s ,E r l a n g e n ,G e rmany) by a single blinded
observer for the assessment of ventricular volumes (end-
diastolic, end-systolic and stroke volumes), function
(ejection fraction) and left ventricular mass [23,25]. Aor-
tic distensibility will be assessed at the ascending aorta
and proximal descending aorta at the level of the pul-
monary artery and the distal descending aorta at the
level of the diaphragm and calculated using previously
validated formulae [26]. Brachial blood pressures will be
simultaneously recorded at the time of scanning.
Dynamic tissue-tagging magnetic resonance imaging
allows direct non-invasive assessment of regional systolic
myocardial shortening and is a previously validated tech-
nique [27]. Spatial modulation of magnetization will be
used to generate a uniform grid pattern with 8 mm tag
separation on the left ventricular myocardium at three
short axis sections (basal, equatorial and apex) and the
horizontal long axis image using a fast field echo multi-
shot sequence (temporal resolution 40-50 ms, repetition
time 3.9 ms, echo time 4.4 ms, voxel size 1.8/1.3/6.0
mm
3, flip angle 14°, tag grid angle 45° with slice thickness
6 mm and a minimum number of 15 phases per cardiac
cycle) with prospective ECG gating as previously
described [28]. The myocardial grid will be followed
through systole for deformation caused by ventricular
contraction. Blinded analysis will be performed offline for
left ventricular longitudinal shortening and apical and
basal rotation as previously described [28].
Pulse Wave Velocity and Pulse Wave Analysis
Pulse wave velocity (SphygmoCor, AtCor Medical, Syd-
ney) will be performed as previously described [29] fol-
lowing 15 minutes of supine rest using a high-fidelity
micromanometer (SPC-301, Millar Instruments, Texas)
to sequentially record ECG-gated carotid and femoral
arterial waveforms. The path length will be calculated
by subtracting the distance between the sternal notch
and carotid recording site from the distance between
the sternal notch and femoral site. This method is
reproducible in both healthy subjects and patients with
renal impairment [30,31]. Pulse wave analysis will be
performed using the micromanometer to flatten, but not
occlude, the radial artery using gentle pressure. Data
will be collected directly into a portable computer and
after 11 seconds of data capture, an averaged peripheral
waveform and corresponding central waveform will be
generated using a validated transfer function. The cen-
tral waveform will be analysed using the system software
to determine the augmentation index (AIx) and central
aortic pulse and systolic pressures. AIx represents the
difference between the second and first peaks of the
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Figure 1 Study timeline. 120 subjects will undergo baseline
investigations before entering a 4 week open-label run-in phase in
which all subjects will receive 1600 mg of sevelamer carbonate with
meals. Participants will then be randomised to continue treatment
with sevelamer carbonate 1600 mg with meals or identical placebo
for the remaining 36 weeks. Safety monitoring will be performed
every four weeks. Investigations will be repeated at week 40 after
which subjects will have completed participation in the study.
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centage of the pulse pressure. Values will be reported as
the mean of three stable readings. This method has
been shown to be reproducible in both healthy subjects
and in patients with renal impairment [30,32]. The
results for AIx will be corrected to a heart rate of 75
beats/minute (AIx75) [33]. All measurements will be
made in triplicate and mean values used in analysis.
Echocardiography
A comprehensive transthoracic echocardiogram (Vivid 7,
GE Vingmed Ultrasound, Horten, Norway) will be per-
formed with the subject in the left lateral decubitus
position by a single experienced echocardiographer
using second harmonic imaging and an M3S multi-fre-
quency transducer. All parameters will be measured in
triplicate and averaged as per the recommendations of
the American Society of Echocardiography [34]. Analysis
will be performed offline by a single blinded observer
using an EchoPAC workstation (GE Vingmed Ultra-
sound, Horten, Norway). Ventricular dimensions, wall
thickness, chamber volumes and stroke volume will be
determined using standard methods [35]. Left ventricu-
lar mass will be determined by the 2-dimensional area--
length formula and indexed to body surface area.
Resting left ventricular diastolic function will be deter-
mined using standard techniques [36]. Peak systolic (s’),
early diastolic (e’) and late diastolic (a’)m i t r a la n n u l a r
velocities will be measured at end expiration at the
septal, lateral, inferior and anterior left ventricular walls
with real time pulsed wave tissue Doppler [37].
Greyscale images for 2-dimensional left ventricular
strain and strain rate imaging will be acquired in cine-
loop format in triplicate from the apical 4-, 2- and 3-
chamber views and parasternal short axis views at basal,
equatorial and apical levels at end expiration at frame
rates >70/second for offline analysis using commercially
available software (Speqle Tracking, GE Healthcare,
United Kingdom). The endocardial border will be manu-
ally tracked at end-systole and the software will then
generate a region of interest that will be placed over the
myocardium. This will enable frame-to-frame tracking
of ultrasonic speckles that change position according to
surrounding tissue motion throughout the cardiac cycle.
Peak systolic velocities, strain, strain rate, rotation and
twist will be measured for each myocardial segment in
triplicate and averaged.
Dual Energy X-ray Absorptiometry Scanning
Dual energy x-ray absorptiometry scanning (Hologic
QDR Series 4500 with Discovery Software version
11.02:03, Hologic Europe, Zaventem, Belgium) will be
used to assess bone mineral density of the lumbar spine
(L1-L4) and both proximal femurs (femoral neck,
Ward’s region, trochanteric region). Scans will be
reported by an experienced bone densitometry clinical
scientist blinded to clinical data.
Run-in Phase
Following baseline studies all subjects will receive 1600 mg
of sevelamer carbonate with meals for 4 weeks during an
open-label run-in phase (Figure 1) to assess tolerability,
efficacy, compliance and side effect profile. The develop-
ment of new symptoms that may relate to treatment and
compliance with medication will be assessed at 2-weekly
intervals during run-in. Serum phosphate will also be mea-
sured at 2-weekly intervals. In the event that serum phos-
phate falls below 0.8 mmol/L, the dose of sevelamer will
be halved to 800 mg with meals (Table 2) and levels
rechecked to ensure serum phosphate is >0.8 mmol/L. If
serum phosphate remains below this level after 6 weeks
and/or a dose reduction subjects will be withdrawn from
the study after a final set of measurements.
Randomisation and Treatment Phase
At the end of the open-label run-in phase subjects will
attend for a second study visit and the following will be
repeated: i) office brachial blood pressure and heart rate
measurement in triplicate; ii) applanation tonometry to
determine aortic pulse wave velocity; iii) applanation
tonometry to derive central pressure waveforms from
pulse wave analysis; iv) collection of serum and plasma
for haematological and biochemical analysis; v) storage of
serum and plasma at -80°C for future assay of biomarkers
associated with cardiovascular function and calcification;
vi) collection of a spot urine sample to determine albu-
min: creatinine ratio; and vii) 24-hour urine collection for
determination of phosphate excretion.
Participants will then be randomised by computer
assignment to continue 1600 mg (or half-dose) sevela-
mer with meals or receive an identical placebo for the
remaining 36 weeks (Figure 1). During this blinded
Table 2 Management of serum phosphate levels during
open-label run-in phase
Serum Phosphate
(mmol/L)
Action
Week 2 <0.8 Reduce dose to 800 mg tds and
continue to week 4
>0.8 Continue to week 4
Week 4 <0.8 Reduce dose to 800 mg tds and
continue to week 6
If already on 800 mg tds withdraw
from study after week 4 visit
>0.8 Randomise
Week 6 <0.8 Final measurements and withdraw
from study
>0.8 Randomise
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renal function and serum calcium, phosphate and PTH
every four weeks. Serum phosphate levels will be mana-
ged according to a pre-defined protocol during the
treatment period (Table 3). All measurements per-
formed at the initial main study visit (except for the
plain lateral abdominal radiograph) will be repeated at a
final visit 40 weeks after baseline studies, marking the
end of subject participation in the study.
Subject Withdrawal
Withdrawal criteria are listed in Table 4. The average
serum phosphate level of patients with stage 3 CKD
enrolled in a previous study by the investigators was
1.2 ± 0.2 mmol/L [38]. It is therefore felt unlikely that
significant numbers of participants will need to be with-
drawn because of hypophosphataemia. The majority of
patients with stage 3 CKD do not require phosphate-
binding medication for overt hyperphosphataemia and
the prevention of metabolic bone disease. Should any
subjects in the placebo group develop serum phosphate
>1.8 mmol/L, they will be withdrawn from the study
and rescue therapy with appropriate phosphate binders
will be administered.
Endpoints
T h ep r i m a r ye n d - p o i n to ft h es t u d yw i l lb ear e d u c t i o n
in left ventricular mass after 40 weeks of treatment. Left
ventricular mass is a powerful predictor of cardiovascu-
lar and all-cause mortality in the general population [39]
and in CKD [40]. A therapeutic reduction in left ventri-
cular mass has been shown to effectively reduce cardio-
vascular morbidity and mortality [41,42]. Secondary end
points are: i) change in aortic compliance measured by
CMR; ii) change in arterial stiffness as assessed using
pulse wave velocity and pulse wave analysis; iii) change
in arterial elastance measured by echocardiography;
iv) change in left ventricular systolic and diastolic
elastance measured by echocardiography; v) change in
left ventricular function as assessed by tissue Doppler
imaging, strain and strain rate analysis and measure-
ment of torsion; and vi) change in bone density on
DEXA scanning and/or magnetic resonance imaging.
Planned Statistical Analysis
Comparisons will be performed between the groups at
baseline and after the 36-week treatment phase. The
normality of distribution of all continuous variables will
be determined using a normality plot and the Kolmo-
gorov-Smirnov test. Normally distributed variables will
be analysed using unpaired t-tests, c
2 or repeated mea-
sures analysis of variance with corrections made for
multiple comparisons. Variables not normally distribu-
ted will be log transformed prior to analysis to achieve
normal distribution or, if this is not achieved, analysed
by Mann-Whitney U or Kruskal-Wallis tests. Multiple
linear regression models will be derived for left ventricu-
lar mass and measures of vascular and cardiac stiffness
using stepwise regression analysis. Analysis will be by
intention-to-treat. A p-value of <0.05 will be considered
statistically significant.
Sample size calculations were based on the primary
endpoint of change in left ventricular mass after
40 weeks of treatment. A previous study by our group
evaluating the cardiovascular effects of spironolactone in
patients with early CKD revealed a 14 g drop in left
ventricular mass from baseline following 40 weeks of
therapy [38]. Using data from this previous study, 55
subjects in each arm will provide at least 80% power of
detecting an 8 g difference between the change in left
ventricular mass from baseline to 40 weeks using a two-
tailed t-test at the 5% significance level given a standard
deviation of 15 g in the change in left ventricular mass
from baseline. Recruiting 60 subjects to each group will
allow a 10% withdrawal or dropout rate.
Table 3 Management of serum phosphate levels during
treatment phase
Serum
Phosphate
(mmol/L)
Action
At visit <0.8 Recheck serum phosphate within 1
week
>0.8 Continue routine 4-weekly checks
Within 1 week
of visit
<0.8 Reduce treatment/placebo dose to
800 mg tds and recheck in 2
weeks
>0.8 Continue routine 4-weekly checks
2 weeks after visit <0.8 Final measurements and withdraw
from study
>0.8 Continue routine 4-weekly checks
Table 4 Withdrawal criteria
Withdrawal Criteria
Pregnancy
Hypophosphataemia (serum PO4 <0.8 mmol/L despite dose reduction
of treatment/placebo)
Hyperphosphataemia (serum PO4 >1.8 mmol/L in subjects receiving
placebo)
Occurrence of any serious adverse event, intercurrent illness or
laboratory abnormality which, in the opinion of the investigators,
warrants the subject’s permanent withdrawal from the study
Poor compliance with study medication
Poor attendance at study visits
Subject inability to tolerate study medication due to side effect profile
Subject decision to withdraw
Deteriorating renal function
Subject lost to follow-up (loss of contact before final study visit)
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All adverse events, including serious adverse events
(SAEs), will be recorded and followed up for the dura-
tion of the study or until resolution. Assessment of
adverse events will be performed by the study investiga-
tors. All SAEs will be graded and reported to the spon-
sor. Any suspected unexpected serious adverse reactions
will be reported to the sponsor, ethics committee and
Medicines and Healthcare products Regulatory Agency.
This study has been reviewed and approved by West
Midlands Research Ethics Committee. Written informed
consent will be obtained from all study participants.
Summary
The demonstration of an important pathophysiological
role for serum phosphate in the development of cardio-
vascular disease associated with CKD would be crucial
in the understanding of this condition and have impor-
tant implications for treatment. As left ventricular mass
and arterial stiffness are prognostically significant
markers in CKD, a positive effect would suggest that
phosphate lowering in stage 3 CKD with the non-
calcium-based phosphate binder sevelamer, in addition
to conventional treatment for blood pressure and
hypercholesterolaemia, is of prognostic value and would
provide a rationale for a large clinical trial with cardio-
vascular morbidity and mortality as end-points.
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